Effects of Tangshen Formula on urinary and plasma liver-type fatty acid binding protein levels in patients with type 2 diabetic kidney disease: post-hoc findings from a multi-center, randomized, double-blind, placebo-controlled trial investigating the efficacy and safety of Tangshen Formula in patients with type 2 diabetic kidney disease

Table 2 Effect of TSF and placebo on Scr, BUN, UAER, eGFR and ln plasma L-FABP levels in patients with microalbuminuria

Parameters	Groups	Baseline	Week 12	Week 24
UAER (μg/min)	TSF	157.6 ± 72.9	115.9 ± 50.7	104.0 ± 32.4^a
UAER (μg/min)	Placebo	158.6 ± 99.0	116.5 ± 69.7	121.8 ± 69.7
BUN (mmol/L)	TSF	5.1 ± 1.2	5.6 ± 1.4	5.5 ± 1.4
BUN (mmol/L)	Placebo	5.7 ± 1.6	6.6 ± 1.5	6.0 ± 2.3
Scr (μmol/L)	TSF	73.5 ± 19.3	64.4 ± 19.7	67.6 ± 16.7
Scr (μmol/L)	Placebo	60.8 ± 18.2	62.7 ± 19.8	61.9 ± 15.1
eGFR (ml/min/1.73 m²)	TSF	102.7 ± 39.2	118.3 ± 49.4	113.9 ± 53.5
eGFR (ml/min/1.73 m²)	Placebo	128.3 ± 61.0	124.8 ± 45.2	121.0 ± 44.0
ln plasma L-FABP (μg/ml)	TSF	1.0 ± 0.9	1.3 ± 0.8	1.2 ± 0.7
ln plasma L-FABP (μg/ml)	Placebo	1.4 ± 0.7	1.7 ± 0.6	1.1 ± 0.7

All values expressed as mean ± SD
^a: P < 0.05 compared with baseline of the same group (Paired t test)
Abbreviations: BUN blood urea nitrogen, eGFR estimated glomerular filtration rate, ln plasma L-FABP ln-transformed plasma liver-type fatty acid binding protein, Scr serum creatinine, UAER urinary albumin excretion rate